by rnossadmin | Nov 18, 2024 | Uncategorized
The safety of medicines is a top priority in the European Union, where regulatory agencies, pharmaceutical companies, and healthcare providers work closely to monitor and manage the risks associated with medicinal products. A critical tool in this effort is the...
by rnossadmin | Oct 22, 2024 | Uncategorized
Understanding the Serious Adverse Events (SAEs) of COVID-19 mRNA Vaccines: An In-Depth Analysis In December 2019, the world was introduced to a novel virus, SARS-CoV-2, which quickly evolved into the global pandemic we know as COVID-19. With the World Health...
by rnossadmin | Oct 22, 2024 | Uncategorized
The Role of the MVA-BN Vaccine in Protecting Children Against Mpox: Recent Findings and Future Directions The global mpox outbreak in May 2022, caused by the clade IIb monkeypox virus, marked the first significant human-to-human transmission of the disease. While mpox...
by rnossadmin | Aug 6, 2024 | Uncategorized
Tedopi® is a novel T-cell epitope-based cancer vaccine targeting five tumor-associated antigens, aimed at expanding tumor-specific T-lymphocytes in HLA-A2 cancer patients. As an off-the-shelf immunotherapy, it has been evaluated in the Phase 3 Atalante-1 trial for...
by rnossadmin | Jul 30, 2024 | Uncategorized
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer, has announced updated efficacy and safety results from the dose-escalation part of their Phase 1/2 study...
